Ind-Swift Laboratories Ltd. (INDSWFTLAB) AI Stock Analysis

• Market Cap: ₹7.40B
• Dividend Yield: N/A
• Average Volume (3M): 7.30K
• Price to Earnings (P/E): 2.6
• Beta (1Y): 1.34
• Revenue Growth: -37.70%
• EPS Growth: -19.79%
• Country: IN
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.00
• Shares Outstanding: 81,611,560
• 10 Day Avg. Volume: 7,859
• 30 Day Avg. Volume: 7,299
• PEG Ratio: -0.04
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.96
• P/FCF Ratio: -5.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: ₹115.00 ▲(26.79% Upside)

Ind-Swift Laboratories Ltd. receives a solid score due to its strong valuation and positive technical indicators. However, cash flow challenges present a risk that needs to be addressed to ensure sustainable growth. The stock's undervaluation offers a compelling investment case, but liquidity issues warrant caution.

Positive Factors

Revenue Growth

The robust sales expansion indicates a growing market presence and effective product demand, supporting long-term business sustainability.

Balance Sheet Strength

Low leverage and a solid equity position provide financial stability and flexibility, enhancing the company's ability to invest in growth opportunities.

Return on Equity

High return on equity indicates effective management and strong profitability, which can attract investors and support sustainable growth.

Negative Factors

Cash Flow Challenges

Persistent cash flow issues can hinder the company's ability to finance operations and growth, posing a risk to long-term financial health.

Negative EBIT Margin

A negative EBIT margin suggests operational inefficiencies or cost pressures that could impact profitability and competitive positioning.

Liquidity Issues

Liquidity constraints can limit the company's ability to meet short-term obligations and invest in strategic initiatives, affecting overall stability.

Ind-Swift Laboratories Ltd. Business Overview & Revenue Model

Company Description

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

How the Company Makes Money

Ind-Swift Laboratories Ltd. generates revenue through multiple key streams, primarily by selling its pharmaceutical products, which include APIs and finished formulations. The company benefits from a robust export business, supplying to various countries, thereby leveraging the global demand for affordable generic medications. Additionally, the company engages in contract manufacturing agreements with other pharmaceutical firms, providing them with production capabilities in exchange for financial compensation. Strategic partnerships with healthcare providers and distributors further enhance its market reach and profitability. Overall, the company’s revenue model is built on a combination of direct sales, exports, and contractual agreements, ensuring a steady flow of income.

Ind-Swift Laboratories Ltd. Financial Statement Overview

Summary

Ind-Swift Laboratories Ltd. shows strong revenue growth and profitability with a robust balance sheet, but faces significant cash flow challenges, indicating potential liquidity issues that need addressing.

Income Statement

Ind-Swift Laboratories Ltd. has shown a strong revenue growth rate of 25.63% in the latest year, indicating robust sales expansion. However, the company experienced a significant drop in EBIT, resulting in a negative EBIT margin for 2025. Despite this, the net profit margin remains healthy due to a substantial net income, suggesting effective cost management or one-time gains.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.0178 in 2025, indicating financial stability and low leverage. The return on equity is impressive at 44.97%, showcasing efficient use of equity to generate profits. The equity ratio is solid, suggesting a stable financial structure.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows in 2025, indicating potential liquidity issues. The free cash flow growth rate is negative, suggesting declining cash generation capabilities. The ratios of operating and free cash flow to net income are unfavorable, highlighting cash flow management concerns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.81B	5.62B	12.81B	12.07B	10.39B	8.91B
Gross Profit	3.48B	2.74B	4.13B	4.40B	4.10B	3.75B
EBITDA	2.87B	2.85B	7.82B	2.36B	2.35B	1.98B
Net Income	2.58B	2.50B	4.21B	475.97M	-21.49M	-31.47M
Balance Sheet
Total Assets	0.00	14.38B	14.60B	18.24B	18.01B	18.18B
Cash, Cash Equivalents and Short-Term Investments	4.67B	4.82B	4.94B	231.54M	333.68M	116.01M
Total Debt	0.00	408.41M	166.22M	8.62B	9.53B	10.05B
Total Liabilities	-11.73B	2.65B	6.48B	11.42B	12.00B	12.15B
Stockholders Equity	11.73B	11.73B	9.36B	6.82B	6.01B	6.04B
Cash Flow
Free Cash Flow	0.00	-898.80M	-2.08B	1.82B	1.32B	1.31B
Operating Cash Flow	0.00	-254.74M	-1.63B	1.95B	1.50B	1.35B
Investing Cash Flow	0.00	-1.10B	-1.23B	-133.68M	47.72M	-101.72M
Financing Cash Flow	0.00	692.05M	6.99B	-1.86B	-1.41B	-1.24B

Ind-Swift Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 90.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Negative. The current price of 90.7 is below the 20-day moving average (MA) of 92.27, below the 50-day MA of 95.75, and below the 200-day MA of 96.38, indicating a bearish trend. The MACD of -1.37 indicates Negative momentum. The RSI at 44.94 is Neutral, neither overbought nor oversold. The STOCH value of 51.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDSWFTLAB.

Ind-Swift Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹9.72B	13.81	―	―	13.32%	218.38%
INDSWFTLAB	70 Outperform	₹7.40B	2.57	―	―	-37.70%	-19.79%
SAKAR	66 Neutral	₹8.34B	43.00	―	―	24.20%	55.01%
ZIMLAB	63 Neutral	₹3.33B	50.60	―	―	-5.82%	-59.22%
MEDICAMEQ	57 Neutral	₹5.29B	47.58	―	0.26%	-9.16%	49.09%
NECLIFE	52 Neutral	₹4.09B	-1.13	―	―	-30.27%	-3470.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Ind-Swift Laboratories Ltd. Corporate Events

Ind-Swift Laboratories Closes Trading Window Ahead of Q3 FY2025 Results

Ind-Swift Laboratories Ltd. has announced the closure of its trading window for company securities from 1 January 2026 until 48 hours after the declaration of its unaudited standalone and consolidated financial results for the quarter ended 31 December 2025. The restriction, which applies to promoters, promoter group members, directors, key managerial personnel, designated persons, connected persons/insiders and their immediate relatives, is in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct, reinforcing compliance and governance standards aimed at preventing insider trading around key financial disclosures.

Ind-Swift Laboratories Completes Intra-Promoter Transmission of 232,057 Shares

Ind-Swift Laboratories Ltd. has informed the stock exchanges that 232,057 equity shares, originally held by the late promoter shareholder Neera Mehta, have now been transmitted to the joint demat account of her three legal heirs, all of whom are part of the company’s promoter and promoter group. The transfer, completed following regulatory approvals linked to the earlier amalgamation of Ind-Swift Limited with Ind-Swift Laboratories Limited and undertaken under an exemption for inter-se promoter transfers in the SEBI takeover regulations, results in no change to the aggregate shareholding of the promoters, signalling a purely intra-family realignment of ownership with no immediate implications for control or public shareholders.

Ind-Swift Laboratories Secures Trading Approval for New Equity Shares Post-Amalgamation

Ind-Swift Laboratories Ltd. has received trading approval from both BSE Limited and the National Stock Exchange of India Limited for over 8.1 million equity shares, each valued at ₹10. This approval follows the company’s Scheme of Amalgamation, where Ind-Swift Limited was merged with Ind-Swift Laboratories Ltd. The shares will be available for trading from December 5, 2025, marking a significant step in the company’s strategic growth and market presence.